MCKINNEY ANTHONY ALEXANDER has a total of 13 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2011. It filed its patents most often in United States, Taiwan and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are NEUROVANCE INC, ATTENUA INC and EPITECH GROUP SRL.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 | |
#2 | Taiwan | 1 | |
#3 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Mckinney Anthony Alexander | 13 |
#2 | Bymaster Frank | 6 |
#3 | Piskorski Walter | 6 |
#4 | Bymaster Franklin Porter | 4 |
#5 | Bymaster Franklin | 3 |
#6 | Engers David A | 2 |
#7 | Smolenskaya Valeriya | 2 |
#8 | Fleitz Fred J | 2 |
#9 | Welter Richard | 1 |
#10 | Marshall Randall | 1 |
Publication | Filing date | Title |
---|---|---|
US2017209415A1 | Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive disorders including nicotine addiction | |
US2016346249A1 | Use of amitifadine, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in methods and compositions with enhanced efficacy and reduced metabolic side effects and toxicity for treatment of depression and other central nervous system disorders and conditions affected by monoamine neurotransmitters | |
US2013123238A1 | Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders |